(Q33832466)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665250%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

review article

1 reference

title

Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665250%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

1 reference

L S Welage

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665250%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

R R Berardi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665250%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 January 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665250%20AND%20SRC:MED&resulttype=core&format=json

Journal of the American Pharmacists Association

3 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665250%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665250%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665250%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

52-62; quiz 121-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665250%20AND%20SRC:MED&resulttype=core&format=json

Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

The role of antisecretory drugs in the treatment of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Proton-pump inhibitors in acid-related diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Helicobacter pylori: rational management options

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Gastroesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

A comparison of five maintenance therapies for reflux esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

The impact of gastroesophageal reflux disease on health-related quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Zollinger-Ellison syndrome. Recognition and management of acid hypersecretion

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Management of patients with Zollinger-Ellison syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Use of omeprazole in patients with Zollinger-Ellison syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

A review on treatment of bleeding peptic ulcer: a collaborative task of gastroenterologist and surgeon

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Drugs for pH control in upper gastrointestinal bleeding.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Results of a placebo-controlled multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Effect of parenteral omeprazole and ranitidine on gastric pH and the outcome of bleeding peptic ulcer.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

A comparison of omeprazole and placebo for bleeding peptic ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Intravenous therapy with high doses of ranitidine and omeprazole in critically ill patients with bleeding peptic ulcerations of the upper intestinal tract: an open randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Omeprazole versus ranitidine as adjunct therapy to endoscopic injection in actively bleeding ulcers: a prospective and randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Lansoprazole in the prophylaxis of acid aspiration during elective surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Effect of oral omeprazole on intragastric pH and volume in women undergoing elective caesarean section

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Acid aspiration prophylaxis for emergency Caesarean section

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Acid aspiration prophylaxis in elective biliary surgery. A comparison of omeprazole and famotidine using manually aided gastric aspiration.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Effect of single-dose omeprazole and ranitidine on gastric juice acidity and volume in patients undergoing laparotomy.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Effect of i.v. omeprazole on the pH and volume of gastric contents before surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Considerations for long-term use of proton-pump inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Omeprazole drug interaction studies

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

The effect of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of methadone

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Omeprazole enhances the efficacy of pancreatin (pancrease) in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Effect of omeprazole on the pharmacokinetics of itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Lansoprazole does not affect the bioavailability of oral contraceptives

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Effects of omeprazole on ethanol metabolism: an in vitro and in vivo rat and human study

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

An evaluation of the CYP1A induction potential of pantoprazole in primary rat hepatocytes: a comparison with other proton pump inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Pharmacokinetic interaction between lansoprazole and theophylline

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Lansoprazole: an alternative method of administration of a capsule dosage formulation

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931036-1

7 January 2021

10.1016/S1086-5802(16)31036-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10665250%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference